Lipid nanoparticle compositions and methods of formulating the same
Provided herein are compositions and methods of reducing adduct formation.
1. A composition comprising a lipid nanoparticle comprising a mRNA, a phospholipid, a cholesterol, a PEG-lipid, and an ionizable lipid,
wherein the ionizable lipid comprises a tertiary amine group and can decompose into one or both of a secondary amine and a reactive aldehyde species capable of interacting with the mRNA to form an ionizable lipid-polynucleotide adduct impurity, and
wherein less than about 10% of the mRNA is in the form of the ionizable lipid-polynucleotide adduct impurity, as measured by reverse phase ion pair high performance liquid chromatography (RP-IP HPLC).
2. The composition of claim 1 , wherein less than about 5% of the mRNA is in the form of the ionizable lipid-polynucleotide adduct impurity.
3. The composition of claim 1 , wherein less than about 1% of the mRNA is in the form of the ionizable lipid-polynucleotide adduct impurity.
4. The composition of claim 1 , wherein the ionizable lipid is selected from:
5. The composition of claim 4 , wherein an amount of the ionizable lipid-polynucleotide adduct impurity increases at an average rate of less than about 2% per day when stored at a temperature of about 25° C. or below.
6. The composition of claim 4 , wherein an amount of the ionizable lipid-polynucleotide adduct impurity increases at an average rate of less than about 0.5% per day when stored at a temperature of about 5° C. or below.
7. The composition of claim 4 , wherein an amount of the ionizable lipid-polynucleotide adduct impurity increases at an average rate of less than about 0.5% per day when stored at a refrigerated temperature.
8. The composition of claim 7 , wherein the refrigerated temperature is about 5° C.
9. The composition of claim 4 , wherein the composition comprises a buffer selected from the group consisting of sodium phosphate, sodium citrate, sodium succinate, histidine histidine-HCl, sodium malate, sodium carbonate, and Tris (tris(hydroxymethyl)aminomethane).
10. The composition of claim 9 , wherein the composition comprises a cryoprotectant.
11. The composition of claim 10 , wherein the cryoprotectant is selected from the group consisting of mannitol, sucrose, trehalose, lactose, glycerol, dextrose, and combinations thereof.
12. The composition of claim 1 , wherein the ionizable lipid-polynucleotide adduct impurity comprises an aldehyde-mRNA adduct impurity.
13. The composition of claim 1 , wherein an amount of lipid aldehydes in the composition is less than about 50 ppm.
14. A composition comprising a lipid nanoparticle comprising a mRNA, a phospholipid, a cholesterol, a PEG-lipid, and an ionizable lipid comprising a tertiary amine group,
wherein less than about 10% of the mRNA is in the form of an ionizable lipid-polynucleotide adduct impurity, as measured by reverse phase ion pair high performance liquid chromatography (RP-IP HPLC), and
wherein an amount of the ionizable lipid-polynucleotide adduct impurity increases at an average rate of less than about 0.5% per day over a period of from 2-10 days when stored at a temperature of about 5° C.
15. The composition of claim 14 , wherein less than about 5% of the mRNA is in the form of an ionizable lipid-polynucleotide adduct impurity.
16. The composition of claim 14 , wherein less than about 1% of the mRNA is in the form of an ionizable lipid-polynucleotide adduct impurity.
17. The composition of claim 14 , wherein the ionizable lipid is selected from:
18. The composition of claim 17 , wherein the amount of the ionizable lipid-polynucleotide adduct impurity increases at an average rate of less than about 2% per day when stored at a temperature of about 25° C. or below.
19. The composition of claim 17 , wherein the composition comprises a buffer selected from the group consisting of sodium phosphate, sodium citrate, sodium succinate, histidine histidine-HCl, sodium malate, sodium carbonate, and Tris (tris(hydroxymethyl)aminomethane).
20. The composition of claim 19 , wherein the composition comprises a cryoprotectant.
21. The composition of claim 20 , wherein the cryoprotectant is selected from the group consisting of mannitol, sucrose, trehalose, lactose, glycerol, dextrose, and combinations thereof.
22. The composition of claim 14 , wherein the ionizable lipid-polynucleotide adduct impurity comprises an aldehyde-mRNA adduct impurity.
23. The composition of claim 14 , wherein an amount of lipid aldehydes in the composition is less than about 50 ppm.
24. The composition of claim 21 , wherein the amount of the ionizable lipid-polynucleotide adduct impurity increases at an average rate of less than about 2% per day when stored at a temperature of about 25° C. or below.
25. The composition of claim 4 , wherein the composition comprises a Tris buffer and sucrose.
26. The composition of claim 25 , wherein the composition comprises a molar ratio of 20-60% ionizable lipid, 5-25% phospholipid, 25-55% cholesterol, and 0.5-15% PEG-lipid, based on the lipid components.
27. The composition of claim 17 , wherein the composition comprises a Tris buffer and sucrose.
28. The composition of claim 27 , wherein the composition comprises a molar ratio of 20-60% ionizable lipid, 5-25% phospholipid, 25-55% cholesterol, and 0.5-15% PEG-lipid, based on the lipid components.
29. A composition comprising a lipid nanoparticle comprising a mRNA, a phospholipid, a cholesterol, a PEG-lipid, and an ionizable lipid,
wherein the ionizable lipid is selected from
and
wherein the composition comprises a Tris buffer and sucrose, and
wherein less than about 10% of the mRNA is in the form of an ionizable lipid-polynucleotide adduct impurity, as measured by reverse phase ion pair high performance liquid chromatography (RP-IP HPLC).